Guidelines on diabetic eye care. the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings
International Journal of Development Research
Guidelines on diabetic eye care. the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings
Received 17th June, 2018; Received in revised form 20th July, 2018; Accepted 09th August, 2018; Published online 29th September, 2018
Copyright © 2018, Dan Călugăru and Mihai Călugăru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors are commenting the article entitled “Guidelines on diabetic eye care. The International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings” published by Wong et al. in Ophthalmology; https://doi. org.10.1016/j.ophtha. 2018.04.007. Published online: May 15, 2018. The conclusion resulting from this article is that regardless of the intravitreal pharmacotherapy chosen, namely, specific (bevacizumab, ranibizumab or aflibercept) or nonspecific (corticosteroid implant) anti-vascular endothelial growth factor agents, the efficacy of the treatment depends primarily on the promptness of the therapy after diabetic macular edema diagnosis. Both groups of anti-vascular endothelial growth factor substances provide similar rates of vision improvement, but with superior anatomic outcomes and fewer injections in the corticosteroid implant-treated eyes. However, more patients receiving the corticosteroid implant lose vision mainly due to cataract.
